Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>AVROBIO, Inc. has ceased to operate as an independent entity following a reverse merger with Tectonic Therapeutic, which closed in June 2024. The combined company now operates under the name Tectonic Therapeutic, Inc. and trades under the ticker 'TECX US'.</li>
  <li>Prior to the merger, AVROBIO was a clinical-stage gene therapy company focused on developing hematopoietic stem cell (HSC) gene therapies for rare diseases. Its pipeline included programs for Gaucher disease, cystinosis, Hunter syndrome, and Pompe disease.</li>
  <li>The acquisition by Tectonic Therapeutic has resulted in the discontinuation of all of AVROBIO's legacy gene therapy programs. The new entity is focused on advancing Tectonic's pipeline of G-protein coupled receptor (GPCR)-targeted therapies.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  AVROBIO, Inc. has ceased to operate as an independent entity following a reverse merger with Tectonic Therapeutic, which closed in June 2024. The combined company now operates under the name Tectonic Therapeutic, Inc. and trades under the ticker 'TECX US'.
  Prior to the merger, AVROBIO was a clinical-stage gene therapy company focused on developing hematopoietic stem cell (HSC) gene therapies for rare diseases. Its pipeline included programs for Gaucher disease, cystinosis, Hunter syndrome, and Pompe disease.
  The acquisition by Tectonic Therapeutic has resulted in the discontinuation of all of AVROBIO's legacy gene therapy programs. The new entity is focused on advancing Tectonic's pipeline of G-protein coupled receptor (GPCR)-targeted therapies.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

United States

Avrobio, Inc. operates as a bio-technology company. The Company develops step-change cell and gene therapies for the treatment of cancer and rare disease. Avrobio serves clients in the United States and Canada.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avrobio Inc (AVRO US)

Primer: Avrobio Inc (AVRO US) - Oct 2025

AVROBIO, Inc. has ceased to operate as an independent entity following a reverse merger with Tectonic Therapeutic, which closed in June 2024....

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)